Track Immunocore Holdings plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immunocore Holdings plc IMCR · Stock Open Immunocore Holdings plc in new tab

29.94 USD
EPS
-0.64
P/B
3.98
ROE
-7.87
Beta
0.81
Target Price
58.90 USD
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
EPS-0.64
Book Value8.13
Price to Book3.98
Debt/Equity103.82
% Insiders0.065%
Growth
Revenue Growth-0.01%
Earnings Growth1.50%
Estimates
Forward P/E-35.95
Forward EPS-0.90
Target Mean Price58.90

DCF valuation

Model fair value for Immunocore Holdings plc (IMCR)
Result
Sign in to run the valuation for IMCR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Buy · mean target 58.90 USD (low 33.00, high 84.00) · as of 11 Nov 2026
Low 33.00
Mean 58.90
High 84.00
Price 29.94
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Immunocore Holdings plc Logo Immunocore Holdings plc Analysis (IMCR)

United Kingdom Health Care Official Website Stock

Is Immunocore Holdings plc a good investment? Immunocore Holdings plc (IMCR) is currently trading at 29.94 USD. Market analysts have a consensus price target of 58.90 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immunocore Holdings plc is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is -0.90.

Investor FAQ

Does Immunocore Holdings plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immunocore Holdings plc?

Immunocore Holdings plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -0.64.

Company Profile

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Exchange Ticker
NMS (United States) IMCR
MUN (Germany) 6YG.MU
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion